News >

Expert Highlights Evolution of BTK Inhibitors in CLL

Jessica Hergert
Published: Tuesday, Feb 18, 2020

Alexey V. Danilov, MD, PhD

Alexey V. Danilov, MD, PhD

In chronic lymphocytic leukemia (CLL), BTK inhibitors as monotherapy and in combination have expanded the armamentarium in both the frontline and relapsed/refractory settings, said Alexey V. Danilov, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication